• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺癌中放射性碘(RAI)的选择性使用:不再“一刀切”。

Selective use of radioactive iodine (RAI) in thyroid cancer: No longer "one size fits all".

机构信息

Department of Surgery, New York Presbyterian/Lower Manhattan Hospital, Weill Cornell Medicine, 156 William Street, 12th Floor New York, NY 10038, USA.

Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue New York, NY 10065, USA.

出版信息

Eur J Surg Oncol. 2018 Mar;44(3):348-356. doi: 10.1016/j.ejso.2017.04.002. Epub 2017 May 3.

DOI:10.1016/j.ejso.2017.04.002
PMID:28545679
Abstract

A remarkable, evidence-based trend toward de-escalation has reformed the practice of radioactive iodine (RAI) administration for thyroid cancer patients. Updated guidelines have supported both decreased RAI doses for select populations, as well as expanded definitions of low-risk and intermediate-risk patients that may not require RAI. Correspondingly, there is now increased flexibility for hemithyroidectomy without need for RAI, and relaxed TSH suppression targets for low-risk thyroidectomy patients. Clinical judgment remains indispensable where multiple risk factors co-exist that individually are not indications for RAI. This is especially salient in intermediate-risk patients with a less than excellent response to therapy, determined through thyroglobulin and ultrasound surveillance. Such judgment, however, may lead to patterns of inappropriate RAI practices or overuse with little benefit to the patient and unnecessary harm. A multidisciplinary, risk-adapted approach is ever more important and obliges the surgeon to understand the likelihood that their patients will receive RAI. The risks and benefits of RAI, its evolved role in contemporary guidelines, and current patterns of use among endocrinologists are reviewed, as well as the practical implications for thyroid surgeons.

摘要

放射性碘 (RAI) 治疗甲状腺癌患者的方案已出现显著的、基于证据的下调趋势,这一趋势改变了实践。更新的指南支持为特定人群减少 RAI 剂量,以及扩大低危和中危患者的定义,这些患者可能不需要 RAI。相应地,对于不需要 RAI 的甲状腺叶切除术,现在有了更大的灵活性,对于低危甲状腺切除术患者,TSH 抑制目标也放宽了。如果存在多种单独不是 RAI 适应证的危险因素,则仍需要临床判断。对于治疗反应不佳的中危患者,通过甲状腺球蛋白和超声监测,这一点尤为明显。然而,这种判断可能导致 RAI 实践的不当模式或过度使用,对患者没有益处,也没有必要造成伤害。多学科、风险适应的方法变得越来越重要,这迫使外科医生了解其患者接受 RAI 的可能性。本文回顾了 RAI 的风险和益处、其在当代指南中的演变作用以及内分泌学家目前的使用模式,以及对甲状腺外科医生的实际影响。

相似文献

1
Selective use of radioactive iodine (RAI) in thyroid cancer: No longer "one size fits all".甲状腺癌中放射性碘(RAI)的选择性使用:不再“一刀切”。
Eur J Surg Oncol. 2018 Mar;44(3):348-356. doi: 10.1016/j.ejso.2017.04.002. Epub 2017 May 3.
2
Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: a practical approach to clinical decision making.分化型甲状腺癌全甲状腺切除术后选择使用放射性碘消融和辅助治疗:临床决策的实用方法。
Oral Oncol. 2013 Jul;49(7):676-83. doi: 10.1016/j.oraloncology.2013.03.444. Epub 2013 Apr 16.
3
Less is More: The Impact of Multidisciplinary Thyroid Conference on the Treatment of Well-Differentiated Thyroid Carcinoma.少即是多:多学科甲状腺会议对分化型甲状腺癌治疗的影响
World J Surg. 2018 Feb;42(2):343-349. doi: 10.1007/s00268-017-4308-9.
4
Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.比较不同剂量放射性碘消融治疗中高危分化型甲状腺癌患者的效果。
Ann Nucl Med. 2019 Jul;33(7):495-501. doi: 10.1007/s12149-019-01357-6. Epub 2019 Apr 6.
5
Referral Practice for Radioactive Iodine Ablation (RAI) after ATA guidelines 2015: results from a Tertiary Cancer Care Centre.放射性碘消融(RAI)后 ATA 指南 2015 的转诊实践:来自三级癌症治疗中心的结果。
Eur Arch Otorhinolaryngol. 2020 Sep;277(9):2521-2526. doi: 10.1007/s00405-020-05946-4. Epub 2020 Apr 2.
6
Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.术后刺激甲状腺球蛋白和颈部超声作为低中危甲状腺乳头状癌风险分层及放射性碘选择的个性化标准
Endocrine. 2015 Sep;50(1):130-7. doi: 10.1007/s12020-015-0575-0. Epub 2015 Mar 20.
7
The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer.临床医生在确定低危甲状腺癌使用放射性碘中的作用。
Cancer. 2013 Jan 15;119(2):259-65. doi: 10.1002/cncr.27721. Epub 2012 Jun 28.
8
Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?低危和中危甲状腺乳头状癌患者甲状腺全切除术后不可检测到甲状腺球蛋白——是否需要放射性碘治疗?
Surgery. 2012 Dec;152(6):1096-105. doi: 10.1016/j.surg.2012.08.034.
9
Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.对于低风险乳头状甲状腺癌患者,了解病理检查与临床检查结果均为阴性的淋巴结情况,与甲状腺切除术后放射性碘使用的减少有关。
Endocrine. 2016 Jun;52(3):579-86. doi: 10.1007/s12020-015-0826-0. Epub 2015 Dec 26.
10
Practice patterns among thyroid cancer surgeons: implications of performing a prophylactic central neck dissection.甲状腺癌外科医生的实践模式:预防性中央区颈淋巴结清扫术的影响
J Otolaryngol Head Neck Surg. 2016 Oct 28;45(1):55. doi: 10.1186/s40463-016-0169-8.

引用本文的文献

1
Treatment outcomes in patients with papillary thyroid cancer undergoing radiofrequency ablation of metastatic lymph nodes.接受转移性淋巴结射频消融治疗的甲状腺乳头状癌患者的治疗结果
Gland Surg. 2024 Oct 31;13(10):1752-1758. doi: 10.21037/gs-24-285. Epub 2024 Oct 26.
2
Assessing the role of central lymph node ratio in predicting recurrence in N1a low-to-intermediate risk papillary thyroid carcinoma.评估中央淋巴结比值在预测 N1a 低-中危甲状腺乳头状癌复发中的作用。
Front Endocrinol (Lausanne). 2023 Sep 14;14:1158826. doi: 10.3389/fendo.2023.1158826. eCollection 2023.
3
Survival benefit of active surveillance for papillary thyroid carcinoma: a propensity score matching analysis based on SEER database.
甲状腺乳头状癌主动监测的生存获益:基于监测、流行病学与最终结果(SEER)数据库的倾向评分匹配分析
Front Oncol. 2023 Jun 9;13:1185650. doi: 10.3389/fonc.2023.1185650. eCollection 2023.
4
Thyroglobulin-Based Risk Factor Repositioning for Determining Radioactive Iodine Activity in Patients with Papillary Thyroid Carcinoma: a Multicenter Retrospective Cohort Study.基于甲状腺球蛋白的风险因素重新定位以确定甲状腺乳头状癌患者的放射性碘活性:一项多中心回顾性队列研究
Nucl Med Mol Imaging. 2022 Aug;56(4):173-180. doi: 10.1007/s13139-022-00756-4. Epub 2022 Jun 18.
5
Radioactive iodine therapy: multiple faces of the same polyhedron.放射性碘治疗:多面的同一种多面体。
Arch Endocrinol Metab. 2022 May 13;66(3):393-406. doi: 10.20945/2359-3997000000461. Epub 2022 May 12.
6
Surgery and Radioactive Iodine Therapeutic Strategy for Patients Greater Than 60 Years of Age with Differentiated Thyroid Cancer.对于年龄大于 60 岁的分化型甲状腺癌患者,手术和放射性碘治疗策略。
J Healthc Eng. 2022 Feb 8;2022:4348396. doi: 10.1155/2022/4348396. eCollection 2022.
7
Impacts of the American Joint Committee on Cancer (AJCC) 8 edition tumor, node, metastasis (TNM) staging system on outcomes of differentiated thyroid cancer in Thai patients.美国癌症联合委员会(AJCC)第8版肿瘤、淋巴结、转移(TNM)分期系统对泰国分化型甲状腺癌患者预后的影响。
Heliyon. 2021 Mar 30;7(3):e06624. doi: 10.1016/j.heliyon.2021.e06624. eCollection 2021 Mar.
8
F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib.使用乐伐替尼治疗的晚期、放射性碘难治性甲状腺癌患者的F-FDG-PET/CT
Cancers (Basel). 2021 Jan 16;13(2):317. doi: 10.3390/cancers13020317.
9
Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis.低危型甲状腺乳头状癌患者早期和延迟放射性碘残余消融后的临床结局:倾向评分匹配分析。
Endocrinol Metab (Seoul). 2020 Dec;35(4):830-837. doi: 10.3803/EnM.2020.747. Epub 2020 Nov 18.
10
The Identification of Intraoperative Risk Factors Can Reduce, but Not Exclude, the Need for Completion Thyroidectomy in Low-Risk Papillary Thyroid Cancer Patients.术中风险因素的识别可以降低,但不能排除低危型甲状腺乳头状癌患者行甲状腺腺叶切除术的必要性。
Thyroid. 2020 Feb;30(2):222-228. doi: 10.1089/thy.2019.0274. Epub 2020 Jan 9.